A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
← catalyst calendarSponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20actual
Sites
6
Countries
Bosnia and Herzegovina, Bulgaria, Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-19 | actual | When the study began enrolling |
| Primary completion | 2026-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Intervention
- Drug: Lu AG22515
Primary outcome
what the primary-completion date above is the date OFChange in Proptosis from Baseline to Week 24 in the Trial Eye Using the Hertel Exophthalmometer
measured Baseline, Week 24
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed